Price
300.85
-0.52%52W Range
Market Cap
₹957.02 Cr
Traded: ₹0.06 Cr (0.01%) 0.0x
Free Float: ₹157.05 Cr (0.04% of FF traded)
Volume · 60D trend
1.86 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +31.0% | +19.0% | +8.0% | -- | +29.0% | Stable |
| ROE | -4.0% | -2.0% | +2.0% | -- | -- | Accelerating |
| Return | +17.0% | -1.0% | +6.0% | +9.0% | -- | Accelerating |
| Profit | +7.0% | +17.0% | +27.0% | -- | -154.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 447 | 374 | 346 | 301 | 298 | 286 | 281 | 274 | 270 | 307 | 375 | 358 | 336 | 313 | 281 | 254 |
| Expenses | 455 | 399 | 356 | 324 | 292 | 311 | 305 | 278 | 273 | 317 | 371 | 355 | 327 | 324 | 291 | 261 |
| Operating Profit | -8 | -25 | -10 | -23 | 6 | -25 | -24 | -5 | -2 | -11 | 3 | 3 | 9 | -11 | -10 | -6 |
| OPM % | -1.9% | -6.7% | -3.0% | -7.5% | 2.0% | -8.8% | -8.4% | -1.7% | -0.9% | -3.5% | 0.9% | 0.9% | 2.8% | -4.0% | -3.6% | -2.0% |
| Other Income | 13 | 13 | 14 | 5 | 25 | 22 | -14 | -167 | 29 | 18 | 20 | 10 | 12 | 9 | 4 | -2 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 |
| Profit Before Tax | 2 | -15 | 1 | -19 | 30 | -5 | -39 | -174 | 25 | 5 | 21 | 11 | 19 | -6 | -9 | -11 |
| Tax % | -0.5% | -12.5% | 59.8% | -17.2% | 11.9% | -478.4% | 2.0% | -13.2% | -102.8% | -583.0% | 3.9% | -23.0% | -28.9% | 288.0% | -70.5% | -273.0% |
| Net Profit | 2 | -13 | 0 | -15 | 27 | 18 | -38 | -155 | 41 | 22 | -3 | -12 | -0 | -48 | -26 | -3 |
| Exceptional Items | 0 | -1 | 0 | -0 | 0 | 0 | -2 | -190 | 1 | 0 | 0 | 0 | 0 | -0 | 0 | -8 |
| EPS (Rs) | 0.8 | -3.5 | 0.4 | -4.0 | 7.5 | 4.3 | -8.5 | -34.4 | 9.8 | 5.2 | -0.2 | -2.5 | 0.4 | -10.8 | -6.0 | -0.4 |
| Sales Growth (YoY) | -- | 30.8% | 22.9% | 10.2% | 10.4% | -6.8% | -24.9% | -23.7% | -19.6% | -2.1% | 33.5% | 41.0% | 75.0% | 100.0% | -- | -- |
| Sales Growth (QoQ) | -- | 8.1% | 14.9% | 1.0% | 4.2% | 1.8% | 2.5% | 1.5% | -12.1% | -17.9% | 4.5% | 6.5% | 7.3% | 11.5% | 10.5% | -- |
| OP Growth (YoY) | -238.3% | 0.0% | 56.3% | -379.0% | 352.5% | -136.6% | -791.0% | -240.1% | -125.9% | 3.2% | 134.0% | 156.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | 66.7% | -143.1% | 54.2% | -473.1% | 124.0% | -6.3% | -402.1% | -96.7% | 77.5% | -410.5% | 1.8% | -63.6% | 184.2% | -9.1% | -68.0% | -- |
| Profit Growth (YoY) | -89.0% | -177.0% | 104.0% | -151.0% | -21.0% | -18.0% | -3362.0% | 402.0% | 2222.0% | 148.0% | 96.0% | -468.0% | 107.0% | -221.0% | -118.0% | 149.0% |
| EPS Growth (YoY) | -- | -181.6% | 104.3% | 88.4% | -23.2% | -16.8% | -3429.2% | -1248.6% | 2287.8% | 148.1% | 96.0% | -553.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -1075.0% | 109.0% | -153.1% | 74.9% | 150.8% | 75.4% | -451.3% | 89.4% | 2254.2% | 90.6% | -722.0% | 103.8% | -79.2% | -1438.5% | -- |
| OP Margin | -- | -6.7% | -2.9% | -7.6% | 2.0% | -8.7% | -8.5% | -1.8% | -0.7% | -3.6% | 0.8% | 0.8% | 2.7% | -3.5% | -3.6% | -2.4% |
| Net Margin | -- | -3.5% | 0.0% | -5.0% | 9.1% | 6.3% | -13.5% | -56.6% | 15.2% | 7.2% | -0.8% | -3.4% | 0.0% | -15.3% | -9.4% | -1.2% |
| Material Cost % | -- | 94.0% | 91.0% | 95.0% | 86.0% | 93.0% | 94.0% | 90.0% | 90.0% | 92.0% | 90.0% | 89.0% | 88.0% | 92.0% | 92.0% | 92.0% |
| Employee Cost % | -- | 7.0% | 6.0% | 7.0% | 6.0% | 6.0% | 4.0% | 4.0% | 4.0% | 4.0% | 3.0% | 4.0% | 4.0% | 4.0% | 4.0% | 5.0% |
| P/S | 0.65 | 0.74 | 0.79 | 0.77 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | 806.97 | 37.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.49 | 1.52 | 1.43 | 1.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find attached the disclosure.
Disclosure under Listing Regulations - Submission of Audio recording of the Earnings Conference call for Q1 FY27
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended 30th June, 2026
Please find attached the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30.06.2026
Please find attached the disclosure
Please find attached the Investor Presentation of the Company
Please find attached the Outcome of Board meeting held on 7th August, 2026
Please find the certificate under Reg 74(5) of SEBI (Depositories and Participants) Reg, 2018 for the quarter ended 30th June, 2026
Intimation of closure of Trading Window
Disclosure under Reg 30 of SEBI (LODR) - Transcript of Group Conference Call
Disclosure under Listing Regulations - Submission of Audio recording of the Group Conference call for Q4 FY26
Please find attached the Investor Presentation.
Please find attached the disclosure
Please find the disclosure attached herewith.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ravi Kant Sharma & PACs
Please find attached the disclosure.
Please find the Intimation for change of website of the Company
Intimation of Schedule of Investors / Analysts Meeting under the SEBI LODR Reg, 2015 and the registration Link
Newspaper publication of the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026
Please find attached herewith the Investor Presentation.
Outcome of Board Meeting for the quarter and year ended March 31, 2026
Audited Financial Results for the quarter and financial year ended March 31, 2026
Intimation of Re-appointment of Internal Auditors of the Company
Annual Secretarial Compliance Report for the financial year ended 31st March, 2026
Health X Platform Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Standalone and ....
Intimation under Reg 30 of SEBI (LODR) Reg 2015 regarding completion of transfer of the entire equity stake of Mitsubishi Corporation held in Sastasundar Healthbuddy Limited, material subsidiary ....
Please find attached the approval received from stock exchanges for change in Name and Symbol.
Please find attached the information.
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Reg, 2018 for the quarter ended March 31, 2026.
Please find attached the disclosure.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Banwari Lal Mittal and Luv Kush Projects Ltd & PACs
Please find attached the disclosure.
This is to inform that the Trading Window shall remain closed from 1st April, 2026 till the conclusion of 48 hours after the declaration of Audited Financial Results for the quarter and ....
Please find attached the disclosure.
Please find attached the disclosure.
Please find attached the disclosure.
Intimation of Schedule of Analysts/ Institutional Investors Meeting under the SEBI (LODR) Reg, 2015
Please find attached the disclosure.
Intimation of Schedule of Analysts/ Institutional Investors Meeting under the SEBI (LODR) Reg, 2015
Please find attached the disclosure.
Please find attached the disclosure
Please find attached the Outcome of Meeting of the Board of Directors held today i.e. 27th February, 2026.
Please find attached the intimation by Sastasundar Healthbuddy Limited, material subsidiary regarding outcome of its board meeting for granting in-principle approval to its restructuring process.
Please find attached the disclosure regarding in-principle approval of Scheme of Arrangement by the Board of Directors of Health X Platform Limited (formerly known as Sastasundar Ventures ....
Please find attached the disclosure.
Announcement under Reg 30 of SEBI (LODR) - Change in Name of the Company from Sastasundar Ventures Limited to Health X Platform Limited.
Please find attached the disclosure.
Please find attached the disclosure.
Please find attached the Earnings Call Transcript for Q3 FY''26.
Please find the update on reduction of share capital of Genu Path Labs Limited, step down subsidiary of the company
Annual Reports
14Concalls
29Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Oct 2024
31 Oct 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jul 2023
31 Jul 2023Mar 2023
31 Mar 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Sep 2022
30 Sept 2022Jun 2022
30 Jun 2022Mar 2022
31 Mar 2022Dec 2021
31 Dec 2021Nov 2021
30 Nov 2021Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2018
31 Aug 2018Feb 2018
28 Feb 2018Nov 2017
30 Nov 2017Held by ETFs
1 ETFs hold HEALTHX · sorted by weight
Held by Mutual Funds
1 schemes hold HEALTHX · sorted by weight